In vitro model: Evercyte has generated telomerized fibroblast cell lines (dermal skin fibroblasts fHDF/TERT166, lung fibroblasts LF/TERT309) that can be grown without limitations while maintaining a primary-like phenotype. Assay set-up:
treatment of telomerized fibroblasts with transforming growth factor ß (TGFß) induces the expression of alpha smooth muscle actin (alpha-SMA), which is a key event in physiological and pathological tissue repair. Using immunofluorescent staining, alpha-SMA expression upon TGFß treatment alone or in combination with potential anti-fibrotic compounds is analysed.Timelines:
depending on the number of compounds to be tested, the number of replicates and concentrations requested, it takes between 3 and 5 weeks to deliver results.
Testing anti-fibrotic activity of compounds / EVs
Treatment of human dermal fibroblasts (fHDF/TERT166) with transforming growth factor ß (TGF-ß) induces the expression of alpha smooth muscle actin (alpha-SMA / green fluorescence, cell nuclei are counterstained with DAPI), which is a key event in physiological and pathological tissue repair.
Extracellular vesicles from mesenchymal stem cells significantly reduce expression of alpha-SMA after TGF-ß treatment (right figure). These data indicate that EVs from mesenchymal stem cells inhibit myofibroblast differentiation and might exert anti-fibrotic activity.